Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥3,225 JPY
Change Today -45.00 / -1.38%
Volume 1.7M
As of 2:00 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

terumo corp (4543) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/15 - ¥3,445
52 Week Low
05/7/14 - ¥1,954
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TERUMO CORP (4543)

Related News

No related news articles were found.

terumo corp (4543) Related Businessweek News

No Related Businessweek News Found

terumo corp (4543) Details

Terumo Corporation manufactures and sells medical products and equipment worldwide. The company operates through Cardiac & Vascular, General Hospital, and Blood Management segments. Its cardiac and vascular products primarily comprise interventional devices that include access devices, such as introducer sheaths, guidewires, and guiding catheters; therapeutic devices, which include balloon catheters and stents; intravascular imaging systems; and cardiopulmonary bypass systems comprising oxygenator with integrated arterial filters, heart-lung machines, and artificial thoracic vascular grafts. The company’s general hospital products principally include infusion systems, including infusion pumps, infusion solutions, IV catheter, and infusion line connectors; drug and devices comprising prefilled syringes and prefillable syringes; nutritional supplements; measuring devices systems with communication functions, such as blood glucose meters, blood pressure monitors, and thermometers; pain management medicines that include analgesic and antiemetic; and closed anticancer drug infusion systems. Its blood management products primarily comprise automated blood collection systems, blood bag systems with leukocyte reduction filters, automated blood component processing system, pathogen reduction technology systems, therapeutic apheresis systems, and cell expansion systems. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

19,263 Employees
Last Reported Date: 06/25/14
Founded in 1921

terumo corp (4543) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

terumo corp (4543) Key Developments

Terumo Corporation Presents at Mizuho New York Healthcare Conference 2015, Mar-02-2015

Terumo Corporation Presents at Mizuho New York Healthcare Conference 2015, Mar-02-2015 . Venue: Omni Berkshire Place, 21 East 52nd Street at Madison Ave, New York, NY 10022, United States. Speakers: Kazuaki Kitabatake, Senior Executive Officer.

Terumo Corporation to Establish New R&D Center in Southern California

Terumo Corporation has announced that it will establish an R&D center in Southern California to reportedly enhance its R&D capability of the coronary and peripheral interventional therapeutic area. Terumo will invest approximately JPY 10 billion to the center and is intending to start the operation in fiscal year 2017. Terumo has decided to build the new R&D center for the development of cutting-edge interventional systems products by leveraging MicroVention's capability and networking resources in a technology area. The facility will also drive forward neurovascular device development lead by MicroVention.

Terumo Corporation Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2015; Provides Dividend Guidance for the Fourth Quarter Ending March 31, 2015

Terumo Corporation reported consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company saw JPY 129.9 billion in sales for a 9% increase over the fiscal year 2013 third quarter, when sales were JPY 119.2 billion. It was also a robust 10% increase from the previous quarter. For the nine months, the company’s sales were JPY 363.2 billion for a 5% year-over-year increase. Operating income was JPY 52.9 billion for a 10% year-over-year increase. This was led by a significant increase in sales. Ordinary income increased 18% to JPY 58.7 billion, with the increase primarily due to the weak yen in the third quarter, which led to an JPY 8.1 billion positive foreign exchange gain. Net profit was JPY 33.4 billion for a 9% decrease from the previous year. This was the result of a JPY 6.4 billion extraordinary loss taken during the third quarter for the transforming of the General Hospital product portfolio in Europe, which the company has announced previously. Conversely, the fiscal year 2013 net profit was JPY 36.9 billion, positively impacted by JPY 6 billion from a settlement. The difference between these extraordinary gains and losses led to a 9% year-over-year decrease in net income. Net income per fully diluted share was JPY 87.40 compared to JPY 97.15 a year ago. Income before income taxes and minority interests was JPY 52,315 million compared to JPY 54,533 million a year ago. Comprehensive income attributable to shareholders of the company was JPY 91,204 million compared to JPY 83,530 million a year ago. The company provided consolidated earnings guidance for the year ending March 31, 2015. For the period, the company expected net sales of JPY 488,000 million, operating income of JPY 64,000 million, ordinary income of JPY 62,000 million and net income of JPY 33,500 million or JPY 88.22 per share. The company provided dividend guidance for the fourth quarter ending March 31, 2015. For the period, the company expected to pay a dividend of JPY 14.50 per share compared to JPY 29 per share paid in the same period a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4543:JP ¥3,225.00 JPY -45.00

4543 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $167.71 USD +1.05
Edwards Lifesciences Corp $143.68 USD +1.78
Hospira Inc $87.88 USD +0.03
Olympus Corp ¥4,450 JPY -10.00
Teleflex Inc $119.89 USD +0.74
View Industry Companies

Industry Analysis


Industry Average

Valuation 4543 Industry Range
Price/Earnings 40.4x
Price/Sales 2.5x
Price/Book 2.1x
Price/Cash Flow 40.2x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TERUMO CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at